15:26:07 EDT Fri 24 May 2024
Enter Symbol
or Name

Q:RNAZ - TRANSCODE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RNAZ - Q0.11.69·1.710.21.70+0.3122.32,049.13,1373,5501.45  1.84  1.4216309.60  0.4215:07:37May 1315 min RT 2¢

Recent Trades - Last 10 of 3550
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-13 08:30U:RNAZNews ReleaseTransCode Therapeutics Open Letter to Shareholders
2024-04-15 09:00U:RNAZNews ReleaseTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
2024-04-03 09:10U:RNAZNews ReleaseTransCode Therapeutics Reports 2023 Results; Provides Business Update
2024-03-28 08:30U:RNAZNews ReleaseTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
2024-03-11 09:00U:RNAZNews ReleaseTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
2024-03-06 16:15U:RNAZNews ReleaseTransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
2024-02-20 08:00U:RNAZNews ReleaseTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode ¢ € ™s RIG-I Agonist Immunotherapeutic
2024-01-31 16:05U:RNAZNews ReleaseNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders ¢ € ™ Equity Requirement and Continued Listing on The Nasdaq Stock Market
2024-01-29 08:30U:RNAZNews ReleaseTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
2024-01-22 16:45U:RNAZNews ReleaseTransCode Therapeutics Announces Closing of $7.25 Million Public Offering
2024-01-18 13:28U:RNAZNews ReleaseTransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
2024-01-12 16:05U:RNAZNews ReleaseTransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
2024-01-11 08:00U:RNAZNews ReleaseTransCode Therapeutics Announces 1-for-40 Reverse Stock Split
2024-01-04 08:05U:RNAZNews ReleaseTransCode Therapeutics Publishes Open Letter Outlining Company ¢ € ™s Progress and Objectives
2023-12-12 08:30U:RNAZNews ReleaseTransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
2023-12-05 09:00U:RNAZNews ReleaseTransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
2023-12-04 16:10U:RNAZNews ReleaseTransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-11-30 14:53U:RNAZNews ReleaseTransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-11-14 16:30U:RNAZNews ReleaseTransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
2023-10-30 16:34U:RNAZNews ReleaseTransCode Therapeutics Withdraws Public Offering